Sinobioway Highlights of 2026 Mid-Year Performance

Sinobioway Pharmaceutical Group (Hong Kong Stock Exchange Code: 01801), a leading biopharmaceutical company focusing on innovative drugs in the fields of oncology, metabolism, cardiovascular, autoimmune, and ophthalmology diseases, announced its 2026 mid-year performance and the company’s 2030 strategic vision. Dr. Yu Dechao, Founder, Chairman, and CEO of Sinobioway Pharmaceutical Group, stated that the company had completed two key transformations in the past fifteen years. The company transitioned from a research-driven biotechnology company to a fully integrated biopharmaceutical enterprise with research, production, and commercialization capabilities from 2016 to 2020. Subsequently, from 2021 to 2025, it transformed into a company achieving over…